Dr. Toni Choueiri, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• International Medical And Technological University School Of Medicine (vignan)

  Medical School, 2000

• English

• Arabic

• BRAF mutations in metanephric adenoma of the kidney, 2012-06-09

• Post-acute COVID-19 syndrome, 2021-03-22

• Data on Medicare eligibility and cancer screening utilization, 2016-02-27

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, 2019-02-16

• Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma, 2015-09-25

• Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open label, randomised, phase 3 trial, 2022-06-07

• The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium, 2013-10-26

• Racial differences in the surgical care of Medicare beneficiaries with localized prostate cancer, 2016-08-31

• Radium-223 dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases, 2018-05-30

• Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma, 2016-06-10

• Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma, 2016-04-19

• Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET), 2012-11-07

• The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma, 2013-07-23

• Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma, 2022-01-04

• Expression levels of DNA damage repair proteins are associated with overall survival in platinum treated advanced urothelial carcinoma, 2015-12-24

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets, 2015-09-26

• Metastatic non clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium (IMDC) Criteria, 2013-05-21

• Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC), 2014-02-14

• The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients, 2013-01-09

• First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and with an Evaluable Primary Renal Tumor in the CheckMate 214 Trial, 2021-11-05

• IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma, 2022-12-16

• Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial, 2020-09-07

• Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset, 2021-12-15

• Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies, 2013-09-23

• Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib, 2014-03-13

• Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma, 2010-11-15

• ABO blood group and risk of renal cell cancer, 2012-07-26

• Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised phase 3 trial, 2019-08-16

• RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Targeted Therapy, 2015-02-26

• Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma, 2018-09-26

• Genomic investigation of etiologic heterogeneity: methodologic challenges, 2014-12-22

• Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic Renal Cell Carcinoma, 2016-02-01

• STATIN USE AND THE RISK OF RENAL CELL CARCINOMA IN 2 PROSPECTIVE US COHORTS, 2011-07-12

• Adrenocortical Carcinoma: The Management of Metastatic Disease, 2014-06-04

• Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma, 2016-05-09

• Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium, 2021-01-18

• First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium, 2019-08-22

• Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer, 2018-02-22

• Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma, 2016-05-11

• Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors, 2015-06-03

• Epigenomic charting and functional annotation of risk loci in renal cell carcinoma, 2023-01-21

• A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis, 2019-04-08

• Prospective Analysis of Genetic Polymorphisms and Risk of Recurrence in Renal Cell Cancer, 2012-12-07

• Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study, 2015-02-17

• Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival Evaluation of Metastasis Sites for Histological Variants of RCC and Association With Survival, 2021-01-21

• Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States, 2015-07-22

• Metabolomic adaptations and correlates of survival to immune checkpoint blockade, 2019-09-25